INFRONT-3

This is a phase 3 double blind, placebo controlled study evaluating the efficacy and safety of AL001 administered intravenously in participants at risk for or with frontotemporal dementia due to heterozygous mutations in the progranulin gene.

Full Name: A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia